According to a study published in the November 6, 2024, online issue of Neurology, the medical journal of the American Academy of Neurology, older people who are sleepy during the day or lose interest in activities due to sleep issues may be more likely to develop a syndrome that can lead to dementia.
People with the syndrome walk slowly and report memory problems, but they do not have a mobility handicap or dementia. Motoric cognitive risk syndrome is a condition that can develop before dementia.
The study found that people with excessive daytime sleepiness and a lack of enthusiasm to get things done were more likely to develop the syndrome than people without those sleep-related issues. The study does not prove that these sleep-related issues cause the syndrome, it only shows an association.
“Our findings emphasize the need for screening for sleep issues,” said study author Victoire Leroy, MD, PhD, of Albert Einstein College of Medicine in the Bronx, New York. “There’s potential that people could get help with their sleep issues and prevent cognitive decline later in life.”
The study included 445 participants, with an average age of 76, who did not have dementia. Participants completed sleep surveys at the beginning of the trial. They were queried about memory problems, and their walking pace was measured on a treadmill at the beginning of the study and then once a year for the next three years.
The sleep assessment included questions about how frequently people had difficulties sleeping because they woke up in the middle of the night, couldn't fall asleep within 30 minutes, or felt too hot or cold, as well as whether they used sleep aids. The question to assess excessive daytime drowsiness asks how frequently people have had problems remaining awake when driving, eating meals, or were engaged in any other activity.
In total, 177 participants fit the category of bad sleepers, whereas 268 satisfied the definition of good sleepers.
At the outset of the trial, 42 participants had motoric cognitive risk syndrome. Throughout the trial, 36 more persons got the condition.
35.5% of patients who experienced extreme daytime sleepiness and a lack of enthusiasm developed the syndrome, compared to 6.7% who did not. After accounting for other factors that could influence the risk of the syndrome, such as age, depression, and other health conditions, researchers discovered that people with excessive daytime sleepiness and a lack of enthusiasm were more than three times more likely to develop the syndrome than those who did not have those sleep-related issues.
“More research needs to be done to look at the relationship between sleep issues and cognitive decline and the role played by motoric cognitive risk syndrome,” Leroy said. “We also need studies to explain the mechanisms that link these sleep disturbances to motoric cognitive risk syndrome and cognitive decline.”
A limitation of the study is that participants reported their own sleep information, so they may not have remembered everything accurately.
The study was supported by the National Institute on Aging.

(Credit - Canva)
A major new study published in the Lancet has found that record numbers of people around the world now have reduced kidney function, a condition known as Chronic Kidney Disease (CKD). This makes CKD one of the most critical public health issues facing the world today.
The number of people struggling with CKD has more than doubled since 1990, jumping from 378 million to a staggering 788 million in 2023. This huge increase is primarily happening because the world's population is both growing and getting older, and CKD is more common in older age.
As a result, CKD is now one of the top 10 causes of death worldwide for the very first time. Approximately 1.5 million people died directly from the condition in 2023. This rapid growth shows just how quickly this disease is spreading and affecting lives globally.
The study revealed that CKD is dangerous not just because it causes kidney failure, but because it also has a deadly connection to your heart.
Impaired kidney function puts stress on the cardiovascular system and is a key risk factor for heart attacks and strokes, contributing to about 12 percent of all heart disease deaths globally.
Furthermore, the condition severely impacts quality of life, ranking as the 12th leading cause of disability by limiting what people can do. The research also clearly pointed out the three biggest lifestyle and health factors that cause CKD: High Blood Sugar (usually from diabetes), High Blood Pressure, and High Body Mass Index (which is a measure of obesity).
To ensure you get timely help, it is important to know what some early signs of kidney disease are, according to the National Kidney Foundation.
A buildup of toxins and waste in your blood, caused by poor kidney function, can make you feel very tired, weak, and may lead to difficulty focusing on tasks or thinking clearly.
Toxins that are not properly filtered out of the blood by the kidneys can remain in your system, making it difficult to fall asleep or stay asleep throughout the night.
When the kidneys can no longer keep the right balance of minerals and nutrients in the blood, it can lead to mineral and bone disease, causing persistent dry and itchy skin.
A need to urinate more often than usual, especially late at night, can signal damaged kidney filters, which increases the urge to go. This needs medical checking.
Healthy kidneys keep blood cells in the body, but damaged filters allow blood to leak into the urine. This may also indicate an infection or kidney stones.
Excessive bubbles or foam in your urine that look like beaten eggs and require multiple flushes to disappear can mean there is a large amount of protein (albumin) leaking into your urine.
Puffiness, especially around the eyes, is often a sign that your kidneys are damaged and leaking large amounts of protein into the urine instead of keeping it in your body.
Decreased kidney function can cause your body to hold onto sodium (salt). This excess fluid retention then leads to noticeable swelling in your feet and ankles.
A general but important sign, a reduced appetite or feeling of sickness can be caused by the buildup of waste products and toxins in the body due to reduced kidney filtering ability.
Impaired kidney function can lead to an imbalance of essential electrolytes, such as low calcium or poorly controlled phosphorus, which often contributes to painful muscle cramping.
The most hopeful finding is that most people with CKD are still in the early stages of the condition.
This is important because early detection and swift treatment can often prevent the disease from progressing to the point where dialysis or a transplant is needed, which are both dramatic and expensive interventions.
Doctors are urging for more urine testing to catch CKD before symptoms even appear. New medications have also become available in recent years that can slow down the disease and protect the heart.
Ultimately, the report strongly argues that since CKD is currently "underdiagnosed and undertreated," a massive, focused effort is needed globally to make sure patients can afford and access treatment as soon as they are diagnosed.
Credits: Canva
The World Health Organization’s November 2024 report revealed that chronic obstructive pulmonary disease (COPD) remains the fourth leading cause of death worldwide. The condition was responsible for an estimated 3.5 million deaths in 2021 according to the latest available global data. COPD is a common and serious lung disease, and the WHO noted that smoking, indoor and outdoor pollution, and harmful inhalants are among its most significant triggers.
Children, too, are increasingly at risk due to high pollution levels, secondhand smoke and early-life respiratory infections. With winter pollution worsening across many Indian cities, especially Delhi NCR, experts say this is the right moment to revisit how COPD can be prevented through everyday habits and early interventions.
COPD is identified as a chronic lung disorder that results in persistent breathlessness, chronic cough and long-term mucus production. According to the pulmonologist, the disease is a major global health burden linked to high levels of mortality and long-term disability across populations.
The condition develops slowly and often goes unnoticed in its early stages. Over time, narrowed airways and irreversible lung damage make breathing progressively more difficult. The pulmonologist explained that the air people breathe plays a crucial role in determining long-term lung health, especially for those living in severely polluted areas.
COPD is primarily caused by the inhalation of harmful particles and gases. These include cigarette smoke, secondhand smoke, indoor pollution from biomass fuel, outdoor smog, chemicals, dust and repeated lung infections. The pulmonologist added that a small percentage of COPD cases are due to a rare genetic condition known as alpha-1 antitrypsin deficiency. In such cases, checking family history becomes important for early detection.
Preventing COPD requires a comprehensive and consistent lifestyle strategy. While quitting smoking remains the single most effective step for protecting the lungs, the pulmonologist stressed that prevention goes far beyond just avoiding cigarettes. Clean air, healthy food, ideal body weight and regular vaccinations all play a key role.
The pulmonologist shared nine essential tips that can help significantly reduce the risk of COPD, particularly for people living in high-pollution regions such as Delhi NCR.
Credits: Canva
A new meta-analysis published in the journal Stroke reports that GLP-1 receptor agonists such as semaglutide may help reduce the risk of ischemic stroke in patients who do not have diabetes. The findings come from a review of preclinical studies and highlight the growing interest in how these widely used drugs may offer benefits beyond blood sugar control.
GLP-1 receptor agonists are a class of medications that mimic a natural hormone called glucagon-like peptide-1. This hormone helps regulate appetite, insulin release and blood sugar levels. Drugs in this category include semaglutide, liraglutide, exenatide, lixisenatide and dulaglutide. Semaglutide is sold under the brand names Wegovy and Ozempic.
These medicines were originally developed for people with type 2 diabetes. Over time, scientists observed additional effects such as reduced appetite, improved metabolic markers and modest cardiovascular protection. This led to their approval for weight management in people without diabetes. Today, GLP-1 drugs are among the most prescribed medications for obesity and are being studied for heart failure, kidney disease and other conditions. However, their potential benefits in non-diabetic patients at risk of stroke remain largely unexplored.
Researchers from Aarhus University in Denmark conducted the meta-analysis to understand whether GLP-1 drugs could reduce the severity or likelihood of acute ischemic stroke in people who do not have diabetes. The team examined 31 preclinical trials conducted between 2011 and 2024. All studies were carried out in rodent models.
The included drugs were given either orally or through subcutaneous injections. The researchers compared animals receiving GLP-1 drugs with those given a placebo. They reviewed outcomes such as infarct volume, neurological recovery and markers of cell injury.
Across the studies, animals treated with GLP-1 drugs showed significantly smaller infarct volumes than those given a placebo. They also demonstrated better neurological function after stroke.
Lead author Michael K. Michaelsen from the department of clinical medicine at Aarhus University wrote that the mechanisms behind these benefits are not yet clear. He noted that the effects appear to extend beyond blood sugar regulation. According to the paper, GLP-1 drugs may act on multiple pathways involved in stroke injury including inflammation, oxidative stress and cell death. The authors observed reductions in oxidative stress markers, inflammatory mediators and indicators of cell death in several trials. However, they cautioned that these findings do not prove causality.
Since all the analyzed studies were in animals, experts say it is too early to conclude whether GLP-1 receptor agonists could improve stroke outcomes in non-diabetic patients. Clinical trials will be needed to confirm whether the neuroprotective effects translate to humans.
The authors noted that if future research shows that these drugs do not affect platelet function or clotting during the acute phase of stroke, they could one day be used even before patients undergo neuroimaging. They wrote that early prehospital administration could potentially offer faster protection during the critical first moments of stroke.
© 2024 Bennett, Coleman & Company Limited